Log in to save to my catalogue

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_517061

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

In this study, the addition of carfilzomib to lenalidomide and dexamethasone improved response rates and overall survival among patients with relapsed multiple myeloma.
Survival rates have improved for patients with multiple myeloma, yet relapse remains common,
1
indicating an ongoing need for new therapeutic approaches. The immunomodulato...

Alternative Titles

Full title

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_swepub_primary_oai_swepub_ki_se_517061

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_517061

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1411321

How to access this item